Enwei Pharmaceutical Co., Ltd.

Announcement on Pledge of Shares by Controlling Shareholder and Shareholders Holding Over 5%

Announcement on the Implementation of 2025 Annual Equity Distribution

Tracking report for Enwei Pharmaceutical Co., Ltd. from CITIC Securities Co., Ltd.

Regular on-site inspection report for continuous supervision of Enwei Pharmaceutical Co., Ltd. from CITIC Securities Co., Ltd.

Report on the training situation of continuous supervision for Enwei Pharmaceutical Co., Ltd. from CITIC Securities Co., Ltd.

Legal Opinion from Beijing Jindu (Chengdu) Law Firm Regarding the 2025 Annual Shareholders' Meeting of Enwei Pharmaceutical Co., Ltd.

Announcement of Resolutions from the 2025 Annual Shareholders' Meeting

CITIC Securities Co., Ltd. Summary Report on Continuous Supervision and Sponsorship of Enwei Pharmaceutical Co., Ltd. for its Initial Public Offering and Listing on the Growth Enterprise Market

Announcement on Joint Investment with Professional Investment Institutions to Establish a Fund

Announcement on the Release of Pledge on Partial Shares by the Controlling Shareholder

Announcement on the Renewal of the Audit Institution for 2026

Independent Director's 2025 Annual Work Report (Peng Gang)

Independent Director's 2025 Annual Work Report (Liu Ya)

Independent Director's 2025 Annual Work Report (Li Chun)

Announcement on the Online Performance Presentation for the 2025 Annual and Q1 2026

Verification Opinion of the Internal Control Self-Evaluation Report of Enwei Pharmaceutical Co., Ltd. for 2025 by CITIC Securities Co., Ltd.

Internal Control Audit Report of Enwei Pharmaceutical Co., Ltd. as of December 31, 2025

2025 Annual Internal Control Self-Evaluation Report

Compensation Management System for Directors and Senior Management

Shareholder Dividend Return Plan for the Next Three Years (2026-2028)

Announcement on the Compensation (Allowance) Plan for Directors and Senior Management for 2026

Special Report on the Storage and Use of Raised Funds for 2025

Notice of the 2025 Annual Shareholders' Meeting

Announcement of the Resolutions of the 11th Meeting of the 3rd Board of Directors

Announcement on the Profit Distribution Plan for the Year 2025

Quarterly Report for Q1 2026

Verification Report on the Storage, Management, and Use of Raised Funds for the Year 2025 by Enwei Pharmaceutical Co., Ltd.

Special Explanation on the Details of Non-recurring Gains and Losses for the Year 2025 by Enwei Pharmaceutical Co., Ltd.

Evaluation Report on the Performance of the Accounting Firm for the Year 2025

Report from the Audit Committee of the Board of Directors on the Evaluation of the Accounting Firm's Performance for the Year 2025 and the Fulfillment of Supervisory Responsibilities

Special Explanation on Non-operating Fund Occupation and Other Related Fund Transactions for the Year 2025 by Enwei Pharmaceutical Co., Ltd.

Summary Table of Non-operating Fund Occupation and Other Related Fund Transactions for the Year 2025

Financial Settlement Report for the Year 2025

Board of Directors Work Report for the Year 2025

Special Opinion from the Board of Directors on the Independence of Independent Directors

Annual Audit Report for the Year 2025

Annual Report for the Year 2025

Summary of the Annual Report for the Year 2025

Announcement on the Release of Pledge of Certain Shares by the Controlling Shareholder and Shareholders Holding More than 5%

Announcement on the pledge of part of the shares by the controlling shareholder and shareholders holding more than 5%

Announcement on the Second Batch of Vesting Results for the 2023 Restricted Stock Incentive Plan and Share Listing

Legal Opinion from Beijing King & Wood (Chengdu) Law Firm on Adjustment Matters of Enwei Pharmaceutical Co., Ltd.'s 2023 Restricted Stock Incentive Plan

Verification Opinion of the Board of Directors' Nomination and Remuneration Committee on the Adjustment of the Grant Price of Second Class Restricted Stock in the 2023 Restricted Stock Incentive Plan

Announcement on Using Partially Idle Raised Funds and Partially Idle Own Funds for Cash Management

Announcement on Adjusting the Grant Price of Second Class Restricted Stock in the 2023 Restricted Stock Incentive Plan

CITIC Securities Co., Ltd. Verification Opinion on Enwei Pharmaceutical Co., Ltd.'s Use of Partially Idle Raised Funds for Cash Management

Resolutions Announcement of the Tenth Meeting of the Third Board of Directors